Breast-Conserving Therapy in Patients With Triple-Negative Breast Cancer
Status:
Not yet recruiting
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Triple-negative breast cancer (TNBC) is an aggressive subtype shown to have a high
risk of locoregional recurrence (LRR) and distant metastasis (DM). The equivalent impact of
breast-conserving therapy (BCT) and mastectomy on disease-free survival in patients with
early breast cancer has been established by a number of large randomized controlled trials
and meta-analysis. However, ongoing dispute exists on whether TNBC is a good candidate for
BCT.
PURPOSE: This prospective, randomized, open, single-center Phase III clinical study is
conducted to compare efficacy and safety of breast-conserving therapy and mastectomy in
treating Chinese patients with early TNBC.